Quotient Limited (NASDAQ:QTNT) shares traded -37.84% lower at $0.23 on Wall Street last session.
In accordance with the data, 1 analysts cover Quotient Limited (NASDAQ:QTNT). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $60.00 and a low of $60.00, we find $60.00. Given the previous closing price of $0.37, this indicates a potential upside of 16116.22 percent. QTNT stock price is now -88.06% away from the 50-day moving average and -98.27% away from the 200-day moving average. The market capitalization of the company currently stands at $0.85M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $60.00 as their price target over the next twelve months.
With the price target of $5, Goldman recently initiated with Neutral rating for Quotient Limited (NASDAQ: QTNT)., while ‘UBS’ rates the stock as ‘Buy’.
In other news, Buckle Isabelle, Director sold 1,014 shares of the company’s stock on Nov 25. The stock was sold for $892 at an average price of $0.88. Upon completion of the transaction, the Director now directly owns 2 shares in the company, valued at $0.46. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 18, Director von Prondzynski Heino sold 25,000 shares of the business’s stock. A total of $29,500 was realized by selling the stock at an average price of $1.18. This leaves the insider owning 10,578 shares of the company worth $2432.94. Insiders disposed of 17,246 shares of company stock worth roughly $3966.5800000000004 over the past 1 year. A total of 1.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in QTNT stock. A new stake in Quotient Limited shares was purchased by KNOTT DAVID M JR during the first quarter worth $9,000. RENAISSANCE TECHNOLOGIES LLC invested $6,000 in shares of QTNT during the first quarter. In the first quarter, VOYA INVESTMENT MANAGEMENT LLC acquired a new stake in Quotient Limited valued at approximately $2,000. VIRTU FINANCIAL LLC acquired a new stake in QTNT for approximately $1,000. UBS GROUP AG purchased a new stake in QTNT valued at around $1,000 in the second quarter. In total, there are 95 active investors with 57.30% ownership of the company’s stock.
Quotient Limited (NASDAQ: QTNT) opened at $0.3500 on Wednesday. During the past 12 months, Quotient Limited has had a low of $0.18 and a high of $105.20. The fifty day moving average price for QTNT is $1.9112 and a two-hundred day moving average price translates $13.3218 for the stock.
The latest earnings results from Quotient Limited (NASDAQ: QTNT) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$0.37, missing analysts’ expectations of -$0.2 by -0.17. This compares to -$9.03 EPS in the same period last year. The company reported revenue of $8.86 million for the quarter, compared to $9.47 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -6.45 percent. For the current quarter, analysts expect QTNT to generate $9.91M in revenue.
Quotient Limited(QTNT) Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
